Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,357
  • Shares Outstanding, K 35,302
  • Annual Sales, $ 18,820 K
  • Annual Income, $ -131,800 K
  • 60-Month Beta 0.63
  • Price/Sales 13.30
  • Price/Cash Flow N/A
  • Price/Book 0.76
Trade SRRK with:

Options Overview Details

View History
  • Implied Volatility 103.98% ( -1.40%)
  • Historical Volatility 91.02%
  • IV Percentile 46%
  • IV Rank 23.72%
  • IV High 291.69% on 05/06/22
  • IV Low 45.61% on 11/24/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 30
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 473
  • Open Int (30-Day) 451

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.68
  • Number of Estimates 7
  • High Estimate -0.43
  • Low Estimate -0.87
  • Prior Year -1.02
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.19 +29.40%
on 09/26/22
9.60 -16.56%
on 09/13/22
-1.00 (-11.10%)
since 09/02/22
3-Month
5.62 +42.53%
on 07/06/22
11.59 -30.89%
on 08/12/22
+2.13 (+36.22%)
since 07/05/22
52-Week
4.32 +85.20%
on 06/02/22
36.43 -78.01%
on 11/17/21
-21.26 (-72.63%)
since 10/05/21

Most Recent Stories

More News
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that...

SRRK : 8.01 (+0.50%)
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role today announced that...

SRRK : 8.01 (+0.50%)
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that...

SRRK : 8.01 (+0.50%)
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two...

SRRK : 8.01 (+0.50%)
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial...

SRRK : 8.01 (+0.50%)
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

FOLD : 10.85 (-0.55%)
SRRK : 8.01 (+0.50%)
BNTX : 137.19 (-0.28%)
PLRX : 22.45 (+3.41%)
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics

Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.

AMRN : 1.1900 (-1.65%)
SRRK : 8.01 (+0.50%)
BNTX : 137.19 (-0.28%)
PLRX : 22.45 (+3.41%)
Repligen (RGEN) Q2 Earnings and Sales Beat Estimates, Stock Up

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

RGEN : 220.56 (+3.28%)
SRRK : 8.01 (+0.50%)
BNTX : 137.19 (-0.28%)
PLRX : 22.45 (+3.41%)
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

RARE : 40.54 (-4.97%)
ABEO : 3.21 (-5.87%)
SRRK : 8.01 (+0.50%)
BNTX : 137.19 (-0.28%)
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that...

SRRK : 8.01 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 8.84
2nd Resistance Point 8.50
1st Resistance Point 8.26
Last Price 8.01
1st Support Level 7.68
2nd Support Level 7.34
3rd Support Level 7.10

See More

52-Week High 36.43
Fibonacci 61.8% 24.17
Fibonacci 50% 20.38
Fibonacci 38.2% 16.59
Last Price 8.01
52-Week Low 4.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar